# US 2015/0105345 A1 · Uses of antagonists of hyaluronan signaling

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0105345 A1
- Document ID: US20150105345A1
- Status: Published application
- Kind: A1
- Application number: 14/398,837
- Filed: 2013-03-08
- Published: 2015-04-16
- Earliest claimed: 2012-05-15
- Assignees: The United States of America, as represented by the Secretary, Dept. of Health and Human Services; Duke University; MUSC Foundation for Research Development; The Universtiy of North Carolina at Chapel Hill
- Applicants: The United States of America, as represented by the Secretary, Dept. of Health and Human Services; Duke University; MUSC Foundation for Research Development; The University of North Carolina at Chapel Hill
- Inventors: Stavros Garantziotis; John W. Hollingsworth; Bryan P. Toole; Jian Liu
- Web page: https://patentgrep.com/patent/US20150105345A1

## CPC

- A61K 31/728: Hyaluronic acid
- A61K 9/0075: {for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles}
- A61K 9/0078: {for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions}
- A61K 9/008: {comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]}
- A61K 31/702: Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
- A61K 31/726: Glycosaminoglycans, i.e. mucopolysaccharides (chondroitin sulfate, dermatan sulfate A61K31/737)
- A61K 31/727: Heparin; Heparan
- A61P 11/06: Antiasthmatics
- A61P 11/08: Bronchodilators
- A61K 31/715: Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Described herein is the finding that hyaluronan antagonists that inhibit hyaluronan signaling are capable of inhibiting airway inflammation and airway hyperresponsiveness (AHR). The present disclosure provides a method of preventing or reducing AHR in a subject suffering from or at risk for AHR by administering a hyaluronan antagonist. Also provided is a method of treating an airway disease or disorder in a subject by administering a hyaluronan antagonist. Hyaluronan antagonists include, for example, heparosan and hyaluronan oligosaccharides (oHAs). In some embodiments, the hyaluronan antagonist is administered locally to the airway, such as with an inhaler or nebulizer.

## Claims

### Claim 1

A method of treating an airway disease or disorder in a subject, or for preventing or reducing airway hyperresponsiveness (AHR) in a subject, comprising:
selecting a subject with an airway disease or disorder, or suffering from or at risk for AHR; and
administering to the subject a therapeutically effective amount of heparosan or a hyaluronan oligosaccharide (oHA), thereby treating the airway disease or disorder or preventing or reducing AHR.

### Claim 2 (depends on 1)

The method of claim 1, wherein the airway disease or disorder is a chronic disease or disorder.

### Claim 3 (depends on 2)

The method of claim 2, wherein the chronic disease or disorder comprises one or more of asthma, chronic obstructive pulmonary disease, cystic fibrosis, obliterative bronchiolitis, diffuse panbronchiolitis or cryptogenic organizing pneumonia.

### Claim 4 (depends on 1)

The method of claim 1, wherein the airway disease or disorder is an acute disease or disorder.

### Claim 5 (depends on 4)

The method of claim 4, wherein the acute disease or disorder comprises one or more of exercise-induced asthma, respiratory infection, acute bronchiolitis, airway hyperresponsiveness, pollution-induced airway injury, chemical-induced airway injury or ventilation-induced airway injury.

### Claim 6 (depends on 1)

The method of claim 1, wherein AHR is triggered by an environmental trigger, a chemical trigger, exertion or stress.

### Claim 7 (depends on 6)

The method of claim 6, wherein the environmental trigger is ozone, particulate matter or an allergen.

### Claim 8 (depends on 6)

The method of claim 6, wherein the hyaluronan antagonist is administered prophylactically prior to exposure to the trigger.

### Claim 9 (depends on 1)

The method of claim 1, wherein the heparosan or oHA is formulated for local delivery to the airway.

### Claim 10 (depends on 9)

The method of claim 9, wherein local delivery comprises aerosol delivery.

### Claim 11 (depends on 10)

The method of claim 10, wherein the heparosan or oHA is formulated for aerosol delivery using an inhaler.

### Claim 12 (depends on 11)

The method of claim 11, wherein the inhaler is a dry powder inhaler.

### Claim 13 (depends on 11)

The method of claim 11, wherein the inhaler is a metered-dose inhaler.

### Claim 14 (depends on 10)

The method of claim 10, wherein the heparosan or oHA is formulated for aerosol delivery using a nebulizer.

### Claim 15 (depends on 1)

The method of claim 1, wherein the heparosan or oHA is administered daily.

### Claim 16 (depends on 1)

The method of claim 1, wherein the heparosan or oHA is administered at a dose of about 1 to about 100 μg.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The method of any one of claims 1-14, wherein the heparosan or oHA is administered at a dose of about 10 to about 50 μg
